Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

INTRODUCTION: Literature is scarce on the combination treatment of ibrutinib and venetoclax (IV) is scarce in relapsed or refractory chronic lymphocytic leukaemia (RR-CLL). Especially, the possibility of stopping ibrutinib in RR-CLL patients in deep remission is unclear. METHODS AND ANALYSIS: In the...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Mark-David, Kater, Arnon P, Mattsson, Mattias, Kersting, Sabina, Ranti, Juha, Thi Tuyet Tran, Hoa, Nasserinejad, Kazem, Niemann, Carsten Utoft
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566731/
https://www.ncbi.nlm.nih.gov/pubmed/33060089
http://dx.doi.org/10.1136/bmjopen-2020-039168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566731/
https://www.ncbi.nlm.nih.gov/pubmed/33060089
http://dx.doi.org/10.1136/bmjopen-2020-039168

Ejemplares similares